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The serine/threonine kinase Polo-like kinase 1 (Plk1)
is overexpressed in many types of human cancers,
and has been implicated as an adverse prognostic
marker for cancer patients. Plk1 localizes to its intra-
cellular anchoring sites via its polo-box domain
(PBD). Here we show that Plk1 can be inhibited by
small molecules which interfere with its intracellular
localization by inhibiting the function of the PBD.
We report the natural product thymoquinone and,
especially, the synthetic thymoquinone derivative
Poloxin as inhibitors of the Plk1 PBD. Both com-
pounds inhibit the function of the Plk1 PBD in vitro,
and cause Plk1 mislocalization, chromosome con-
gression defects, mitotic arrest, and apoptosis in
HeLa cells. Our data validate the Plk1 PBD as an
anticancer target and provide a rationale for develop-
ing thymoquinone derivatives as anticancer drugs.
INTRODUCTION
The serine/threonine kinasePolo-like kinase 1 (Plk1) is a regulator
of multiple stages of mitotic progression. It is overexpressed in
many types of human cancers, and has been implicated as an
adverse prognostic marker for cancer patients (Barr et al.,
2004; McInnes et al., 2005; Strebhardt and Ullrich, 2006). Its
inhibition in cancer cells by small interfering RNA (Liu and
Erikson, 2003; Spankuch-Schmitt et al., 2002a), a Plk1-derived
peptide (Yuan et al., 2002), antisense oligonucleotides (Span-
kuch-Schmitt et al., 2002b), and small-molecule inhibitors of its
catalytic activity (Gumireddy et al., 2005; Lansing et al., 2007;
Lenart et al., 2007; Liu et al., 2005; McInnes et al., 2006; Peters
et al., 2006; Santamaria et al., 2007; Steegmaier et al., 2007;
Stevenson et al., 2002) has been uniformly demonstrated to in-
duce mitotic arrest and apoptosis of cancer cells in vitro and
in vivo. Inhibition ofPlk1bysmall-molecule inhibitorsof its catalytic
activity is currently being explored in clinical settings (Gumireddy
et al., 2005; Steegmaier et al., 2007). Plk1 localizes to its intracel-
lular anchoring sites via its carboxy-terminal portion containing
the polo-box domain (PBD). The PBD consists of two conservedChemistry & Biologydomains referred to as polo boxes, each of which exhibits folds
based on a six-stranded b sheet and an a helix, which associate
to form a 12-stranded b sandwich domain. Phosphoserine/
phosphothreonine-containing peptides comprising an S-(pT/
pS)-(P/X) motif (Elia et al., 2003a) bind along a positively charged
cleft between the two polo boxes (Cheng et al., 2003; Elia et al.,
2003b). Because the PBD is unique to the family of Plks and is
essential for Plk functions, the PBD is ideally suited to the explo-
ration of the feasibility of inhibiting a serine/threonine kinase by
interfering with its intracellular localization, rather than targeting
the conserved ATP binding site. Moreover, small molecules tar-
geting the PBD should be useful research tools to decipher the
biological role of the Plk1 PBD in mammalian cells. Here we re-
port our discovery that the natural product thymoquinone and
its synthetic derivative Poloxin inhibit the functions of the Plk1
PBD in vitro and in HeLa cells. To our knowledge, this represents
the first report of nonpeptidic inhibitors of the Plk1 PBD.
RESULTS
We have developed a fluorescence polarization assay based on
binding of the Plk1 PBD to a fluorophore-labeled peptide com-
prising its optimal recognition motif (Elia et al., 2003a). Screening
of diverse chemical libraries consisting of 22,461 small mole-
cules for compounds which could interfere with the function
of the Plk1 PBD led to the identification of Poloxin (1) (polo-box
domain inhibitor) (apparent IC50 of 4.8 ± 1.3 mM) (Figures 1A
and 1B; see Table S1 in the Supplemental Data available with
this article online). Poloxin’s IC50 values against the PBDs of
Plk2 and Plk3 (Elia et al., 2003b) as the most stringent specificity
controls were approximately 4-fold and 11-fold higher, respec-
tively (apparent IC50: Plk2 PBD: 18.7 ± 1.8 mM; Plk3 PBD: 53.9 ±
8.5 mM) in analogous fluorescence polarization assays. Due to
its diversity, the screening library did not contain analogs of
Poloxin, from which preliminary structure-activity relationships
might have been inferred. Poloxin’s core structure is represented
by the natural product thymoquinone (2) (Figure 1A). Thymoqui-
none is the bioactive constituent of the volatile oil of black seed
(Nigella sativa), and is well known for its anti-inflammatory and
anti-oxidant activities (Gali-Muhtasib et al., 2006). Moreover,
numerous studies have demonstrated thymoquinone’s po-
tent antineoplastic activity, which seems to be specific for cancer15, 459–466, May 2008 ª2008 Elsevier Ltd All rights reserved 459
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rectmolecular targets that could explain its antineoplastic activity
have not been reported to date. We found that thymoquinone in-
hibited the function of the Plk1 PBD even more potently than Po-
loxin (apparent IC50: 1.14 ± 0.04 mM), but displayed a less desir-
able specificity profile in that it also affected other subtypes of
phosphothreonine/phosphoserine binding domains (Chk2 FHA
domain and Pin1 WW domain) and the phosphotyrosine binding
Src homology 2 (SH2) domain of STAT3 (Figure 1C; Table S1).
Figure 1. Poloxin and Thymoquinone Inhibit the Plk1 PBD
(A) Chemical structures of Poloxin (1) and thymoquinone (2).
(B) Effect of Poloxin on binding of fluorescein-labeled phosphopeptides to
their respective protein domains assayed by fluorescence polarization. Error
bars represent standard deviations (SD).
(C) Effect of thymoquinone on binding of fluorescein-labeled phosphopeptides
to their respective protein domains assayed by fluorescence polarization. Error
bars represent SD.460 Chemistry & Biology 15, 459–466, May 2008 ª2008 Elsevier LtdThus, our data suggest that the Plk1 PBD represents a direct
molecular target of thymoquinone that could explain its antineo-
plastic activity.
Inhibition of the Plk1 PBD by both Poloxin and thymoquinone
was time dependent, opening the possibility that covalent
protein modification may in part contribute to the inhibitor-pro-
tein interaction (Figures S1A and S1B). Supporting evidence
for covalent modification of Plk1 by Poloxin could arise from
experimental approaches which involve incubation of the protein
with Poloxin, subsequent tryptic/chymotryptic digest, and iden-
tification of peptides by mass spectrometry. Attempts to identify
a nucleophilic amino acid modified by Poloxin, however, re-
mained inconclusive. It is conceivable that an amino acid which
might have been modified by Poloxin was part of the protein
sequence which was not detected in the mass spectrometric
analysis; alternatively, protein modification via Michael addition
of a nucleophilic amino acid side chain to one of the activated
double bonds of Poloxin, or condensation of Poloxin’s carbonyl
group with a lysine side chain, could have been lost during sam-
ple preparation due to the reversible nature of these chemical
reactions. Structural data would be required to clarify the pro-
tein-inhibitor interactions.
Due to the fundamental role of Plk1 in various stages of mito-
sis, inhibition of Plk1 by any interfering agent is expected to
increase the mitotic index. Mitotic arrest was furthermore
observed in tumor cells in which mislocalization of endogenous
Plk1 was induced by overexpression of the PBD (Fink et al.,
2007; Hanisch et al., 2006; Jiang et al., 2006; Figures S2A and
S2B). Consistent with this view, both Poloxin and thymoquinone
increased the mitotic index of HeLa cells synchronized by G1/S
arrest 14 hr after the release into media containing the test com-
pounds in a dose-dependent manner, as detected by visual
inspection of cells under the microscope (Figure 2A, white
bars). Most HeLa cells treated with DMSO only as control
reached mitosis 9–10 hr after release from aphidicolin-induced
G1/S arrest (data not shown). Protein levels of Plk1 are known
to increase through G2 phase, peak in M phase, and sharply
decrease on exit from mitosis (Barr et al., 2004; Strebhardt and
Ullrich, 2006). In order to rule out that the increase in the mitotic
index observed 14 hr after release from G1/S arrest was caused
by a delay in progression through S phase, in which Plk1 levels
are low, cells were released into inhibitor-free media for the first
7 hr, and treated with media containing the test compounds for
the next 7 hr (Figure 2A, black bars). Mitotic indices were not
decreased under these experimental conditions, arguing against
the possibility of off-target effects in S phase as the cause for the
mitotic arrest in HeLa cells. Rather, we observed a slight increase
in themitotic indices when the compounds were added 7 hr after
G1/S release, possibly because the later addition of the com-
pounds limited the potential for their degradation or inactivation
by the components of the tissue culture media. To ensure that all
cells, including those entering mitosis earlier than 7 hr after G1/S
release, were exposed to the test compounds before mitotic
entry, and that the cells were continuously exposed to approxi-
mately equal concentrations of intact test compounds, the in-
hibitors were added at the time of G1/S release, followed by an
exchange of the tissue culturemedia withmedia containing fresh
compounds 7 hr later. Analysis of mitotic indices was performed
14 hr after G1/S release (Figure 2A, gray bars).All rights reserved
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(A) Mitotic indices of HeLa cells 14 hr after release from G1/S block. Cells were released into medium containing the test compounds at the time of the release
(0 hr), 7 hr after release (7 hr), or both (0 hr + 7 hr). The number of mitotic cells within a population of 200–300 cells was counted (n = 3). Error bars represent SD.
(B) HeLa cells were synchronized by thymidine block and released into medium containing Poloxin or thymoquinone (TQ) at the indicated concentrations as
described in Experimental Procedures. Unsynchronized cells (control), cells synchronized with nocodazole (Noc) or thymidine (Thym), or cells released from
thymidine block in the medium containing only DMSO (DMSO) were analyzed for comparison.
(C) Analysis of cell-cycle distribution by fluorescence-activated cell sorting. Cells were treated as in (B). A representative example is shown.
(D) Quantification of the cell-cycle analysis as shown in (C) (n = 3). Quantification of the cell-cycle profile in the presence of 25 mM TQwas unfeasible due to toxic
side effects. Error bars represent SD.The induction of mitotic arrest by both compounds was con-
firmed in western blot analysis demonstrating a dose-dependent
increase of hyperphosphorylated Cdc25C, a characteristic fea-
ture of mitotic cells. Furthermore, we noticed an increase in the
concentration of the mitotic markers Plk1, phosphohistone H3,
and cyclin B1 (Figure 2B). Mitotic arrest was confirmed by fluo-
rescence-activated cell sorting (FACS), which revealed an
increase of cells in G2/M phase and a concomitant decrease in
the G0/G1 population for both compounds (Figures 2C and 2D).
Thus, even though thymoquinone was about four to five
times more active than Poloxin in vitro, the compounds’ effi-
cacy to induce mitotic arrest was comparable at a concentra-
tion of 10 mM (Figure 2A), possibly because thymoquinone’s
less selective mode of action decreased the effective con-
centration available for inhibiting the Plk1 PBD. At 25 mM,
thymoquinone displayed toxic side effects, especially underChemistry & Biologythe conditions used for the western blot and FACS analysis
(Figures 2B–2D), preventing the quantitative comparison of
the compounds’ activities.
Mislocalization of Plk1 by overexpression of the Plk1 PBD in
HeLa cells had been reported to allow for bipolar spindle forma-
tion with properly separated centrosomes. However, most PBD-
overexpressing cells were arrested in a prometaphase state due
to chromosome congression defects, and clear metaphase
plates were rarely observed (Hanisch et al., 2006). Consistent
with the literature data, overexpression of the Plk1 PBD led to
a strong increase in cells arrested in prometaphase (Figure S2C).
Among the cell population arrested in metaphase, the majority
displayed chromosome congression defects (Figures S2C and
S2D). In contrast, overexpression of an inactive PBD triple
mutant had no significant effect on the mitotic index and the
distribution of mitotic phases (Figure S2). Consistent with the15, 459–466, May 2008 ª2008 Elsevier Ltd All rights reserved 461
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Plk1 Polo-Box Domain InhibitorsFigure 3. Poloxin and Thymoquinone Induce Chromosome Congression Defects and Mislocalization of Plk1 in HeLa Cells
(A) Distribution of mitotic phases and chromosome congression defects within the total metaphase population in the presence of Poloxin and thymoquinone.
Populations of approximately 50 mitotic cells were analyzed (n = 3). Error bars represent SD.
(B) Poloxin and thymoquinone (TQ) induce chromosome congression defects in HeLa cells. Scale bars represent 5 mm.
(C) Poloxin and thymoquinone (TQ) interfere with localization of Plk1 to the centrosomes and kinetochores in metaphase. The scale bar represents 5 mm.
(D) Quantitative analysis of the effects of Poloxin, thymoquinone, and nocodazole (Noc) on centrosomal Plk1 localization in prometaphase and metaphase
(Poloxin and thymoquinone) or prometaphase only (nocodazole) (n = 20). *p < 105 compared to DMSO. **p < 107 compared to DMSO. p values were calculated
using Student’s t test (unpaired, one-sided). Error bars represent SD.idea that the inhibitors induce mislocalization of Plk1 by interfer-
ing with the function of the PBD, we observed a dose-dependent
increase of cells arrested in prometaphase (Figure 3A) in the
presence of Poloxin and thymoquinone. Among the cells that
were arrested in a metaphase-like state, we noticed a dose-
dependent increase of cells in which single or multiple chromo-
somes had failed to congress to the metaphase plate (Figures
3A and 3B). The percentage of metaphase cells with chromo-
some congression defects increased from 7% in the DMSO con-
trol to 12%, 21%, and 54% in the presence of 5 mM, 10 mM, and
25 mM Poloxin, respectively. A lesser increase of metaphase
cells with chromosome congression defects was observed for
thymoquinone (9%, 16%, and 30% in the presence of 5 mM,
10 mM, and 25 mM thymoquinone), indicative of a lower degree
of intracellular specificity as compared to Poloxin. The faithful462 Chemistry & Biology 15, 459–466, May 2008 ª2008 Elsevier Ltdrecapitulation of the phenotypic effect of the PBD overexpres-
sion by Poloxin in a strongly dose-dependent manner suggests
that Poloxin interferes with correct localization of Plk1 by target-
ing the Plk1 PBD as the dominant mode of action.
In order to further validate that the mitotic arrest and the
chromosome congression defects observed in the presence of
the inhibitors were caused by incorrect distribution of endoge-
nous Plk1, we analyzed the localization of Plk1 by immunofluo-
rescence. In metaphase of DMSO-treated control cells, Plk1
located to centrosomes and kinetochores (Figure 3C). In con-
trast, in the presence of thymoquinone and Poloxin, both centro-
somal and kinetochoral localization of Plk1 were significantly
reduced in metaphase-arrested cells (Figure 3C). Similarly, cen-
trosomal localization of Plk1 in prometaphase was strongly
reduced in the presence of Poloxin and thymoquinone, butAll rights reserved
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Induce Apoptosis in HeLa Cells
HeLa cells were treated with Poloxin or thymoqui-
none (TQ) at the indicated concentrations for 24 hr.
Nontreated cells (control), or cells treated with the
apoptosis-inducing agent camptothecine (Camp),
were analyzed for comparison. Annexin V and
propidium iodide staining were performed as
described in the Experimental Procedures. An-
nexin V staining alone (Ann+) indicates early
apoptotic cells, while double staining by both
Annexin V and propidium iodide (Ann+/PI+) indi-
cates late apoptotic cells. Staining by propidium
iodide alone (PI+) indicates necrotic cells. Error
bars represent SD.was not significantly affected in cells arrested in prometaphase
by nocodazole treatment (Figure S3). Quantification of centroso-
mal Plk1 localization in prometaphase- and metaphase-arrested
cells revealed a highly significant decrease in the presence of
Poloxin and thymoquinone (Figure 3D). These data confirm the
activities of the compounds against the function of the Plk1
PBD observed in vitro (Figures 1B and 1C; Table S1) in the cellu-
lar environment.
Inhibition of Plk1 functions by small-molecule inhibitors of its
catalytic activity (Gumireddy et al., 2005; Lansing et al., 2007;
Lenart et al., 2007; Liu et al., 2005; McInnes et al., 2006; Peters
et al., 2006; Santamaria et al., 2007; Steegmaier et al., 2007;
Stevenson et al., 2002) or RNAi-mediated depletion (Liu andErik-
son, 2003; Spankuch-Schmitt et al., 2002a) induces apoptosis in
cancer cells. In order to investigate whether interference with the
intracellular localization of Plk1 is sufficient to cause apoptosis,
unsynchronizedHeLa cells were treatedwith Poloxin and thymo-
quinone, and were analyzed for Annexin V and propidium iodide
staining by flow cytometry. The apoptotic frequency of HeLa
cells was significantly increased in the presence of 25 mM
Poloxin. Thymoquinone was found to increase the apoptotic fre-
quency of HeLa cells already at 10 mM, but induced a significant
degree of necrosis at 25 mM (Figure 4).
DISCUSSION
Plk1 is widely considered to be a target for anticancer therapy. A
number of small-molecule inhibitors of the enzymatic function of
Plk1 have been reported (Lansing et al., 2007; Lenart et al., 2007;
Liu et al., 2005; McInnes et al., 2006; Peters et al., 2006; Santa-
maria et al., 2007; Steegmaier et al., 2007; Stevenson et al.,
2002), which, with one exception (Gumireddy et al., 2005), are
thought to exert their activities at least in part by competing for
the ATP binding pocket. Clinical trials with small-molecule inhib-
itors of Plk1’s catalytic activity are ongoing (Gumireddy et al.,
2005; Steegmaier et al., 2007). Because the conserved nature
of theATPbinding pocket poses a serious hurdle for the develop-
ment of monospecific inhibitors, careful analysis of the com-
pounds’ activities on all kinases is necessary in order to select
compounds which inhibit the right set of kinases. In fact, due to
the redundancy of signaling pathways and the genetic instability
of cancer cells, multitargeted inhibitors might be of superior ther-
apeutic benefit than truly monospecific ligands of a kinase’s ATP
binding pocket (Daub et al., 2004). Nevertheless, the difficulties
associatedwith the specificities of ATP-competitive kinase inhib-Chemistry & Biologyitors encouraged us to explore an alternativemodeof inhibition of
Plk1.
The Plk1 PBD had been suggested as an ideal target for
cancer therapy due to its unique nature which could facilitate
the development of specific agents targeting its function (Elia
et al., 2003b; Strebhardt and Ullrich, 2006). In this study, we
explored the concept of inhibiting the Plk1 PBD by cell-perme-
able small molecules which prevent it from binding to its intracel-
lular anchoring sites and substrates. Our data demonstrate that
small molecules which interfere with the binding properties of the
Plk1 PBD can cause mitotic arrest and apoptosis in cancer cells,
and thus validate the Plk1 PBD as an anticancer target.
We chose the assay principle of fluorescence polarization
(Owicki, 2000) for the primary screen, as this assay type is ideally
suited to the identification of small-molecule inhibitors of binding
between components of biological systems, such as inhibitors of
DNA-protein interactions (Kiessling et al., 2006; Rishi et al., 2005)
or peptide-protein interactions (Coleman et al., 2005; Schust
et al., 2006). Recently, the scope of fluorescence polarization
assays was expanded to screen for inhibitors of a protein-
aptamer interaction, which led to the identification of a small-
molecule inhibitor of a guanine nucleotide exchange factor
(Hafner et al., 2006).
Despite thymoquinone’s well-documented antineoplastic ef-
fects, clinical trials which could validate the benefit of thymoqui-
none or derivatives thereof for cancer patients have not been
initiated. The lack of information about the molecular targets
underlying thymoquinone’s anticancer activity poses a serious
hurdle to drug development—such knowledge would facilitate
medicinal chemistry efforts aimed at improving the compound’s
pharmacological properties to the level required for drugs, and
also the preselection of patients who are likely to respond in clin-
ical trials (Corson and Crews, 2007). Thus, the discovery of the
Plk1 PBD, and also of the STAT3 SH2 domain, as molecular tar-
gets of thymoquinone not only suggests a rational explanation
for this natural product’s antineoplastic effects (Gali-Muhtasib
et al., 2006) but also provides a strong argument for the develop-
ment of thymoquinone derivatives as anticancer drugs. More-
over, our data add thymoquinone to the very short list of natural
products known to inhibit a protein-protein interaction. Never-
theless, it is to be expected that thymoquinone has additional
molecular targets related to its anticancer activities that were
not uncovered in this study. The PBD inhibitor Poloxin, a syn-
thetic derivative of thymoquinone, already displays a superior
specificity profile in vitro and in cells. In addition, Poloxin offers15, 459–466, May 2008 ª2008 Elsevier Ltd All rights reserved 463
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open the door for examining the function of the PBD in the con-
text of cell-division dynamics. Finally, the specificity profiles of
agents targeting the unique PBD like Poloxin are potentially
more straightforward to analyze and manage than those of
ATP-competitive kinase inhibitors. Thus, our study could have
significant implications for anticancer therapy.
SIGNIFICANCE
Polo-like kinase 1 (Plk1) is a key player for multiple stages of
mitosis, and has been established as a target for anticancer
therapy. Usually, inhibitors of Plk1 target the conserved ATP
binding site. In this manuscript, we provide proof of principle
that Plk1 can alternatively be targeted by small molecules
which inhibit the function of the polo-box domain (PBD), a
recently discovered protein domain which mediates intra-
cellular localization of Plk1. To our knowledge, the natural
product thymoquinone and a synthetic derivative dubbed
‘‘Poloxin’’ identified by us are the first reported nonpeptidic
inhibitors of the protein-protein interactions mediated by the
Plk1 PBD. The compounds interfere with correct localization
of Plk1, and thereby lead to mitotic arrest and apoptosis of
cancer cells. Our data provide an explanation for the anti-
cancer activity of the natural product thymoquinone, and
make it one of the very few natural products known to inhibit
a protein-protein interaction. Poloxin’s more selective activ-
ity against the PBD should make it an excellent tool for
analyzing the role of the PBD in mammalian cells, and has
implications for the future design of anticancer drugs.
EXPERIMENTAL PROCEDURES
Plasmid Construction and Protein Expression
DNA sequences coding for human Plk1 amino acids 326–603, human Plk2
amino acids 355–685, and human Plk3 amino acids 335–646 comprising the
respective polo-box domains (Elia et al., 2003b) were amplified by PCR from
plasmid DNA (Plk1) or placenta cDNA (Plk2, Plk3) and cloned into a modified
pET28a (Plk1) vector, or into amodified pQE70 vector carrying a C-terminal 63
His tag and an N-terminal MBP tag (Plk2 and Plk3). Similarly, nucleotides cod-
ing for the forkhead-associated domain (FHA) of the kinase Chk2 (amino acids
1–225) (Durocher et al., 2000) and the WW domain of the proline isomerase
Pin1 (amino acids 1–162) (Yaffe et al., 1997) were amplified by PCR from
HeLa S3 and placenta cDNA, respectively, and cloned into a modified
pET28a vector. Site-directed mutagenesis of the Plk1 PBD was applied to
generate the inactive Plk1 PBD mutant displaying three mutations: W414F,
H538A, and K540A (PBD FAA) (Schmidt et al., 2006). Wild-type and mutant
PBD sequences were cloned into a modified pCS2 mammalian expression
vector carrying a myc tag. Proteins were expressed from Rosetta BL21DE3
(Novagen) following the published procedure (Schust and Berg, 2004; Schust
et al., 2006), purified by affinity chromatography, and dialyzed against a buffer
containing 50 mM Tris (pH 8.0), 200 mM NaCl (for Plk1: 400 mM NaCl), 1 mM
EDTA, 1 mM dithiothreitol, 10% glycerol, and 0.1% Nonidet P-40. The design
of expression plasmids coding for STAT1, STAT3, and STAT5b as well as their
expression and purification has been described (Schust and Berg, 2004;
Schust et al., 2006).
High-Throughput Screening and Fluorescence Polarization Assays
Diverse chemical libraries consisting of 22,461 small molecules (8,298
molecules from ChemDiv, 9,000 molecules from Maybridge [Hits Kit 9000],
and 5,163 miscellaneous organic molecules) were tested in a fluorescence
polarization assay which analyzes binding between 5-carboxyfluorescein-
GPMQSpTPLNG-OH (final concentration: 10 nM) and the Plk1 polo-box464 Chemistry & Biology 15, 459–466, May 2008 ª2008 Elsevier Ltddomain (final concentration: 65 nM). The final concentration of buffer compo-
nents used was 10 mM Tris (pH 8.0), 50 mM NaCl, 1 mM EDTA, 0.1% Nonidet
P-40, and 10% DMSO. The following fluorophore-labeled peptides were used
for specificity assays: Plk2: 5-carboxyfluorescein-GPMQTSpTPKNG-OH;
Plk3: 5-carboxyfluorescein-GPLATSpTPKNG-OH; Chk2: 5-carboxyfluores-
cein-GHFDpTYLIRR-OH; Pin1: 5-carboxyfluorescein-GWFYpSPRLKK-OH;
STAT1: 5-carboxyfluorescein-GpYDKPHVL-OH; STAT3: 5-carboxyfluores-
cein-GpYLPQTV-NH2; STAT5b: 5-carboxyfluorescein-GpYLVLDKW-OH;
Lck: 5-carboxyfluorescein-GpYEEIP-OH. Proteins were incubated at 22C
with the test compounds for 1 hr prior to addition of the fluorophore-labeled
peptides, and fluorescence polarization was analyzed immediately thereafter.
Proteins were used at the following final concentrations, which correspond
approximately to the Kd values of the respective assays: Plk1: 65 nM; Plk2:
130 nM; Plk3: 1875 nM; Chk2: 240 nM; Pin1: 1000 nM; STAT1: 120 nM;
STAT3: 160 nM; STAT5b: 110 nM; Lck: 40 nM. Fluorescein-labeled peptides
were >95% pure. Inhibition curves were fitted using SigmaPlot (SPSS Science
Software).
Chemical Compounds
Poloxin (1) was purchased from ChemDiv (compound code 1436-0018) and
purified by reverse-phase HPLC. Identity and purity were furthermore verified
by mass spectrometry and 400 MHz 1H-NMR (>97%). Thymoquinone was
purchased from Sigma-Aldrich, and its identity and purity were verified by
mass spectrometry and 400 MHz 1H-NMR (>97%).
Cell culture, transient transfection of cells, cellular extract preparation, and
western blot analysis are described in the Supplemental Data.
Cell-Cycle Analysis
For the determination of mitotic indices shown in Figure 2A, the number of
mitotic cells treated as described below under ‘‘Immunofluorescence Assay’’
within a population of 200–300 cells was counted. For the determination of the
mitotic phase distribution shown in Figure 3A, populations of approximately 50
mitotic cells were analyzed. All experiments were performed in triplicate. For
the cell-cycle analysis shown in Figures 2C and 2D, cells were harvested,
washed with PBS, fixed in chilled 70% ethanol at 4C for 30 min, treated
with 1 mg/ml of RNase A (Sigma-Aldrich) for 30 min, and stained with
100 mg/ml of propidium iodide. The DNA content of 30,000 cells was deter-
mined with a FACScan flow cytometer (BD Biosciences). The data were
analyzed with cell-cycle analysis software MODFIT LT 2.0 (Verity Software
House). All experiments were performed in triplicate.
Apoptosis Assay
Apoptosis was assessed using Vybrant apoptosis assay kit 2 according to the
manufacturer’s instructions (Molecular Probes).
Immunofluorescence Assay
HeLa cells were grown on coverslips for 24 hr and arrested in G1/S by addition
of 1 mg/ml aphidicolin for 14 hr. Cells were released into aphidicolin-free
medium containing the indicated concentration of compounds at a final
DMSO concentration of 0.5%. Nocodazole was used at a final concentration
of 150 nM. After 7 hr, the medium was replaced with fresh medium which
also contained the indicated concentration of compound. Fourteen hours after
the initial release, cells were fixed and permeabilized in methanol for 15 min
at 20C. Cells were washed in PBS and incubated for 60 min in blocking
solution (PBS with 0.1% Tween 20, 1% goat serum). All antibodies were
diluted in blocking solution, and incubations were carried out for 1 hr at
room temperature in a humidified chamber followed by three washes with
PBS containing 0.1% Tween 20. The following antibodies were used: mouse
monoclonal anti-g-tubulin (1:1000; Sigma-Aldrich), which was detected with
Alexa Fluor 546-conjugated goat anti-mouse (1:1000; Molecular Probes),
mouse monoclonal anti-a-tubulin-FITC (1:500; Sigma-Aldrich), and rabbit
polyclonal anti-Plk1 (1:75;Abcam),whichwasdetectedbyAlexaFluor488-con-
jugated goat anti-rabbit (1:1000; Molecular Probes). DNA was stained with
40,6-diamidino-2-phenylindole (2 mg/ml; Sigma-Aldrich). Immunofluorescence
microscopy was performed on a DeltaVision microscope (Applied Precision)
at 1003 magnification. Images were processed using a deconvolution algo-
rithm of Softworx software (Applied Precision). The centrosomal/cytoplasmic
ratioofPlk1stainingwasdeterminedbymeasuring the total intensity in acircularAll rights reserved
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in three cytoplasmic regions of the same size. For quantification, nondecon-
volved images with identical exposure times were used.
SUPPLEMENTAL DATA
Supplemental Data contain three figures, one table, and experimental proce-
dures for cell culture, transient transfection of cells, cellular extract prepara-
tion, and western blot analysis and can be found with this article online at
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